COMPLIVISE Label
Compare more than documents. Manage the complete label lifecycle.
Launch appCCDS v7.2 → regional label comparison
Section 4.4 Special warnings · 3 country labels in scope
SmPC — Germany, v4.1
Warning paragraph absent; wording added in CCDS v7.2
Update required
Variation type IB · due 04 Sep
USPI — United States, v3.8
Equivalent wording present under Warnings and Precautions
Aligned — no change
Verified by K. Rao
PIL — India, v2.4
Patient-facing wording pending translation review
Implementation overdue
M. Shah · due 22 Aug
Differences are held at section level, with approval and effective dates per market. · Illustrative product experience.
How the work moves, end to end.
- What enters
- CCDS, SmPC, USPI, PIL and regional labels with version, effective and approval dates held in a structured repository.
- What is assessed
- Section-level difference detection across documents and countries, with label-impact assessment against the triggering change.
- What action follows
- Review and approval cycles, implementation tracking per market and downstream submission handoffs.
- What evidence remains
- Version history, section-level differences, approver identity, effective dates and closure records per country.
What it does.
- CCDS comparison
- SmPC comparison
- USPI comparison
- PIL comparison
- Regional-label comparison
- Section-level difference detection
- Label repository
- Country-specific labels
- Version history
- Effective and approval dates
- Label-impact assessment
- Review and approval
- Implementation tracking
- Closure evidence
Next layer
COMPLIVISE Quality
Simple quality management designed for pharmaceutical teams.